Prenatal exposure to cigarette smoke and benign breast disease

Epidemiology

Volumn 21, Issue 5, 2010, Pages 736-743

  Liu, Tianli ^a,b   Gatsonis, Constantine A ^b   Baylin, Ana ^b,c   Buka, Stephen L ^b  

^a PEKING UNIVERSITY   (China)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; BREAST DISEASE; CHILD; CIGARETTE SMOKING; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MATERNAL SMOKING; NEWBORN; PREGNANCY; PRENATAL EXPOSURE; PRIORITY JOURNAL; PROGENY;

ADOLESCENT; ADULT; AGE FACTORS; BREAST DISEASES; CHILD; CHILD, PRESCHOOL; CONFIDENCE INTERVALS; FEMALE; HUMANS; INFANT; MATERNAL AGE; NEW ENGLAND; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RISK; SMOKING; TOBACCO SMOKE POLLUTION;

EID: 77955925631     PISSN: 10443983     EISSN: None     Source Type: Journal    
DOI: 10.1097/EDE.0b013e3181e9c118     Document Type: Article

References (31)

1. Norwood SL. Fibrocystic breast disease. An update and review. J Obstet Gynecol Neonatal Nurs. 1990;19:116-121.
2. Goehring C, Morabia A. Epidemiology of benign breast disease, with special attention to histologic types. Epidemiol Rev. 1997;19:310-327.
3. Marchant DJ. Benign breast disease. Obstet Gynecol Clin North Am. 2002;29:1-20.
4. Hecht SS. Tobacco smoke carcinogens and breast cancer. Environ Mol Mutagen. 2002;39:119-126.
5. Terry PD, Rohan TE. Cigarette smoking and the risk of breast cancer in women: a review of the literature. Cancer Epidemiol Biomarkers Prev. 2002;11(10 pt 1):953-971.
6. Rohan TE. Cigarette smoking and risk of benign proliferative epithelial disorders of the breast. Eur J Epidemiol. 1999;15:529-535.
7. Cui Y, Page DL, Chlebowski RT, et al. Cigarette smoking and risk of benign proliferative epithelial disorders of the breast in the Women's Health Initiative. Cancer Causes Control. 2007;18:431-438.
8. Wolff MS, Collman GW, Barrett JC, Huff J. Breast cancer and environmental risk factors: epidemiological and experimental findings. Annu Rev Pharmacol Toxicol. 1996;36:573-596.
9. Anderson LM, Diwan BA, Fear NT, Roman E. Critical windows of exposure for children's health: cancer in human epidemiological studies and neoplasms in experimental animal models. Environ Health Perspect. 2000;108(suppl 3):573-594.
10. Perera FP, Tang D, Tu YH, et al. Biomarkers in maternal and newborn blood indicate heightened fetal susceptibility to procarcinogenic DNA damage. Environ Health Perspect. 2004;112:1133-1136.
11. Lackmann GM, Salzberger U, Tollner U, Chen M, Carmella SG, Hecht SS. Metabolites of a tobacco-specific carcinogen in urine from newborns. J Natl Cancer Inst. 1999;91:459-465.
12. Hansen C, Sorensen LD, Asmussen I, Autrup H. Transplacental exposure to tobacco smoke in human-adduct formation in placenta and umbilical cord bloodvessels. Teratog Carcinog Mutagen. 1992;12:51-60.
13. Slotkin TA. Fetal nicotine or cocaine exposure: which one is worse? J Pharmacol Exp Ther. 1998;285:931-945.
14. Niswander KR, Gordon M. The women and their pregnancies: the collaborative perinatal study of the National Institute of Neurological Diseases and Stroke. Washington, DC: National Institutes of Health; 1972.
15. Klebanoff MA, Levine RJ, Clemens JD, DerSimonian R, Wilkins DG Serum cotinine concentration and self-reported smoking during pregnancy. Am J Epidemiol. 1998;148:259-262.
16. National Center for Health Statistics. Data File Documentation, National Health Interview Survey, 1997 (machine readable data file and documentation). Hyattsville, MD: National Center for Health Statistics; 2000a.
17. Chinyama CN. Benign Breast Diseases: Radiology, Pathology, Risk Assessment. New York: Springer; 2004.
18. Nyirjesy I, Billingsley FS. Benign breast disease. Curr Opin Obstet Gynecol. 1993;5:744-749.
19. McNutt LA, Wu C, Xue X, Hafner JP. Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol. 2003;157:940-943.
20. Brown NM, Manzolillo PA, Zhang JX, Wang J, Lamartiniere CA. Prenatal TCDD and predisposition to mammary cancer in the rat. Carcinogenesis. 1998;19:1623-1629.
21. Machala M, Vondracek J, Blaha L, Ciganek M, Neca JV. Aryl hydrocarbon receptor-mediated activity of mutagenic polycyclic aromatic hydrocarbons determined using in vitro reporter gene assay. MutatRes. 2001;497:49-62.
22. Christou M, Savas U, Schroeder S, et al. Cytochromes CYP1A1 and CYP1B1 in the rat mammary gland: cell-specific expression and regulation by polycyclic aromatic hydrocarbons and hormones. Mol Cell Endocrinol. 1995;115:41-50.
23. Muto T, Wakui S, Imano N, et al. Mammary gland differentiation in female rats after prenatal exposure to 3,3',4,4',5-pentachlorobiphenyl. Toxicology. 2002;177:197-205.
24. Rodier PM. Developing brain as a target of toxicity. Environ Health Perspect. 1995;103(suppl 6):73-76.
25. Robinson JE, Birch RA, Taylor JA, Foster DL, Padmanabhan V. In utero programming of sexually differentiated gonadotrophin releasing hormone (GnRH) secretion. Domest Anim Endocrinol. 2002;23: 43-52.
26. Su X, Colditz GA, Willett WC, et al. Genetic variation and circulating levels of IGF-I and IGFBP-3 in relation to risk of proliferative benign breast disease. Int J Cancer. 2010;126:180-190.
27. Rothman KJ, Greenland S. Modern Epidemiology. 2nd ed. Philadelphia: Lippincott-Raven; 1998.
28. Skov T, Deddens J, Petersen MR, Endahl L. Prevalence proportion ratios: estimation and hypothesis testing. Int J Epidemiol. 1998;27: 91-95.
29. Hartmann LC, Sellers TA, Frost MH, et al. Benign breast disease and the risk of breast cancer. N Engl J Med. 2005;353:229-237.
30. Marshall LM, Hunter DJ, Connolly JL, et al. Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. Cancer Epidemiol Biomarkers Prev. 1997;6:297-301.
31. Page DL, Schuyler PA, Dupont WD, Jensen RA, Plummer WD Jr, Simpson JF. Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. Lancet. 2003;361:125-129.